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Abstract Research in bone tissue engineering is focused on
the development of alternatives to autologous bone grafts
for bone reconstruction. Although multiple stem cell-based
products and biomaterials are currently being investigated,
comparative studies are rarely achieved to evaluate the most
appropriate approach in this context. Here, we aimed to
compare different clinically relevant bone tissue engineer-
ing methods and evaluated the kinetic repair and the bone
healing efﬁciency supported by mesenchymal stem cells
and two different biomaterials, a new hydrogel scaffold and
a commercial hydroxyapatite/tricalcium phosphate ceramic,
alone or in combination.
Syngeneic mesenchymal stem cells (5× 105) and mac-
roporous biphasic calcium phosphate ceramic granules
(Calciresorb C35®, Ceraver) or porous pullulan/dextran-
based hydrogel scaffold were implanted alone or combined
in a drilled-hole bone defect in rats. Using quantitative
microtomography measurements and qualitative histologi-
cal examinations, their osteogenic properties were evaluated
7, 30, and 90 days after implantation. Three months after
surgery, only minimal repair was evidenced in control rats
while newly mineralized bone was massively observed in
animals treated with either hydrogels (bone volume/tissue
volume= 20%) or ceramics (bone volume/tissue volume=
26%). Repair mechanism and resorption kinetics were
strikingly different: rapidly-resorbed hydrogels induced a
dense bone mineralization from the edges of the defect
while ceramics triggered newly woven bone formation in
close contact with the ceramic surface that remained unre-
sorbed. Delivery of mesenchymal stem cells in combination
with these biomaterials enhanced both bone healing (>20%)
and neovascularization after 1 month, mainly in hydrogel.
Osteogenic and angiogenic properties combined with
rapid resorption make hydrogels a promising alternative to
ceramics for bone repair by cell therapy.
1 Introduction
Bone reconstruction after tumors, traumas or pathologies is
a common challenge encountered in regenerative medicine.
To date, autologous bone graft is the gold standard to treat
such injuries but this method is greatly restricted by
important morbidities related to the bone graft collection
procedure [1] and there is a crucial need for developing new
bone substitutes. In recent years, a better understanding of
the biological process underlying bone tissue repair led to
approaches based on a combination of scaffolds with
osteoprogenitor cells.
Scaffolds must be selected for their ability to optimize
bone healing, promote cell survival, proliferation and
differentiation and must be nonimmunogeneic, while exhi-
biting appropriate degradation, mechanical strength and
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ﬂexibility properties. Most commonly approved biomater-
ials are hydroxyapatite (HA) and tricalcium phosphate
(TCP)-mixed scaffolds according to their natural bone
mineral similarities and their biocompatibility and bior-
eactivity. However, HA/TCP ceramics exhibit extensive
in situ resorption latencies preventing the gradual replace-
ment with newly formed bone [2]. Biomaterial design is
expanding with new material syntheses, including synthetic
polymers, ﬁbrous scaffold, bioactive ceramics, metals,
composite scaffolds, and processing techniques to enhance
the complexity of 3D environments [3–5]. A growing
interest for polymer hydrogels to enhance bone healing is
arising on the basis of their easy shaping capacity, radio-
transparency and high resorption ability.
Multiple stem cell-based products have been used in
humans for tissue regeneration. Mesenchymal stem cells
(MSCs) are promising candidates and this is particularly
true within the ﬁeld of bone regeneration since they dif-
ferentiate into osteoblasts, the mature cells responsible for
bone formation. Their great potential in regenerative med-
icine also lies on their in vitro expansion ability as well as
their anti-inﬂammatory and pro-angiogenic properties. If the
physiology and the differentiation ability of MSCs have
been extensively studied in vitro, the fate of these pro-
genitors during in vivo bone metabolism and bone repair
processes remains poorly understood [6, 7].
Several investigations suggested that natural bone heal-
ing response involves the mobilization of endogenous
MSCs from bone marrow to the site of injury and their
subsequent differentiation into osteoblasts to participate in
the bone repair process. This natural bone healing
mechanism can be potentially enhanced by administering
exogenous cultured MSCs combined with artiﬁcial scaf-
folds to bone defect [8–10]. Thus, Granero–Molto et al.
showed in a stabilized tibia fracture mouse model that
transplanted MSCs migrate to the fracture site, contribute to
the repair process initiation and have a key role in the
inﬂammatory response, thus participating to each fracture
healing stages [11]. Li et al. conﬁrmed this contribution of
transplanted MSCs in a mouse model of osteogenesis
imperfecta [12]. They speculated that transplanted cells
induced differentiation or recruitment of endogenous cells
to initiate reparative process at early stages of bone repair.
Several animal studies have evidenced the MSC and
biomaterials-osteogenic properties and some clinical studies
have suggested a beneﬁcial effect of HA/TCP ceramics
colonized with MSCs on bone repair in patients [9, 13–16].
Despite these valuable progresses, bone tissue engineering
is not part of routine clinical practice, underlying the need
for further animal and clinical investigations to deﬁne
optimal combinations biomaterial/osteoprogenitor cells and
understand their mechanisms of action in the bone healing
process.
The present study compared the bone healing process
induced with a porous pullulan/dextran-based hydrogel
scaffold that has already successfully been used in vitro for
cardiovascular engineering applications [17–19] or a com-
mercial HA/TCP ceramic, alone or combined with MSCs,
in a rat femoral drilled-hole bone defect. Microtomography
and histology analysis were used to compare their respec-
tive efﬁciency up to 3 months after implantation.
2 Materials and methods
2.1 Culture of rat bone marrow MSCs
Bone marrow was ﬂushed through the medullary cavity of
femurs collected from syngeneic Lewis rats. Collected bone
marrow cells were expanded in minimal alpha medium
(αMEM; Gibco) supplemented with 1% penicillin/strepto-
mycin (Life Technologies, France), 10% fetal bovine serum
(Hyclone; Thermoscientiﬁc), and 1 ng/mL basic-ﬁbroblast
growth factor (bFGF; Peprotech, France) in an incubator at
37 °C with 5% CO2 and 95% humidity. Plastic-adherent
cells (i.e. MSCs) were subcultured every 4–7 days, and then
characterized by ﬂow cytometry analysis using
phycoerythrin-labeled anti-CD45 (Immunotech) and ﬂuor-
escein isothiocyanate (FITC)-labeled anti-CD90 (Becton
Dickinson) antibodies. MSCs were also characterized by
their capacity to differentiate along adipogenic, chondro-
genic, and osteoblastic lineages as previously speciﬁed [20].
Quantum dot®-labeled MSCs were transplanted to our
experimental rat models to perform in vivo cell tracking
study. Quantum dot® nanocrystals integrate the MSCs
cytoplasm and exhibit intense photostable ﬂuorescence
in vivo for at least 4 months [21].
2.2 Preparation of implants
Macroporous biphasic calcium phosphate ceramic granules
(Calciresorb C35®, HA/TCP= 65/35) were obtained from
Ceraver, France (Fig. 1a–c). To promote cell adhesion on
granules, 5× 105 harvested MSCs were suspended in 200
µL αMEM culture medium and transferred into a tube
containing a single C35 granule. After 2 h in a 37 °C
incubator, granules with adherent MSCs were placed into 6-
well plates and cultured for 4 days prior implantation.
Polysaccharide-based hydrogel scaffolds were synthe-
sized and characterized as previously described [22].
Brieﬂy, hydrogels were prepared using a mix of pullulan
(MW 200,000; Hayashibara) and dextran (MW 500,000;
Sigma) in distilled water. Chemical cross-linking of these
polysaccharides was carried out using the cross-linking
reagent sodium trimetaphosphate (STMP; Sigma) under
alkaline conditions, with addition of porogen reagent
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sodium carbonate (Na2CO3, Sigma). Pore size and inter-
connectivity were selected in order to optimize cell inﬁl-
tration [17]. We demonstrated that calcium carbonate
porogen agent caused the formation of large pores of about
200 μm, favorable for MSCs inﬁltration [22, 23] while
sodium chloride would create smaller pores (40 μm) that
would allow seeding of smaller cells such as endothelial
cells [24]. On this basis, we produced 200 μm diameter
pores, round-shaped porous scaffolds of 6 mm diameter and
1 mm thickness (Fig. 1d), cellularized with 5× 105 MSCs
in 20 μL αMEM culture medium (15 min, 37 °C) immedi-
ately before surgical implantation.
2.3 In vivo implantations
All animal treatment and procedures were approved by the
Institutional Animal Care and Research Advisory Com-
mittee of IRBA in accordance with French law and main
international guidelines. Adult male Lewis rats (Janvier, Le
Genest-St-Isle; France) weighing 220–250 g were bilat-
erally implanted for 7, 30, and 90 days, providing 10 sam-
ples per biomaterial condition and experimental time.
● “Control” group with no speciﬁc treatment;
● “MSC” group with 5× 105 rat MSCs in 20 µL culture
medium;
● “Hydrogel” group with culture medium-hydrated hydro-
gel;
● “Hydrogel+MSC” group with hydrogel cellularized
with 5× 105 rat MSCs;
● “C35” group with culture medium-hydrated calcire-
sorb35® granules;
● “C35+MSC” group with calciresorb35® cellularized
with 5× 105 rat MSCs.
Defects were achieved by drilling a 3 mm diameter hole
through the anterolateral cortical bone into the metaphyseal
cancellous bone marrow, under continuous irrigation with
saline. Osseous cavities were carefully ﬁlled with the dif-
ferent implants and then, muscles and skin were sutured in
different layers (Vicryl®4/0). Analgesia was achieved
through subcutaneous injections of buprenorphine hydro-
chloride (30 µg/kg, Buprecare, Animalcare, UK) 2 h after
surgery and twice a day over three consecutive days.
All rats were sacriﬁced by overdose injections of sodium
pentobarbital (Dolethal, Vétoquinol, France), then femurs
Fig. 1 Assessment of MSC-scaffolds colonization. Scaffolds were
seeded with 5.105 rat MSCs. After 4 days of culture, the MSCs
colonization of Calcirecorb35® granule is conﬁrmed by Trypan blue
staining (a), or scanning electron microscopy at the granule surface (b)
and at macropore entrance (c). Dehydrated porous polysaccharide
scaffold (d) was seeded with MSCs immediately before implantation
and cell inﬁltration within the transparent hydrogel (e) was assessed
microscopically after 10 min, with cell clusters observed within the
hydrogel pores (f). Arrows indicate cells on/in biomaterials
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were collected and ﬁxed in 4% paraformaldehyde for X-ray
microtomography (µCT) and histological analysis.
To measure mineral apposition rate (MAR) at day 30,
calcein ﬂuorochrom (75 mg/kg, Merck) was intraper-
itoneally injected to rats, 12 and 3 days before sacriﬁce.
Calcein is incorporated in the mineralization front by the
time of injection [25].
2.3.1 X-ray microtomography (µCT) analysis
Femurs were scanned using a SkyScan 1174 tomograph
(SkyScan, Belgium) with the following parameter setup:
source energy at 50 keV, intensity of 800 µA and isotropic
voxel resolution of 15 µm with a 0.5 mm depth aluminum
ﬁlter. After 3D reconstructions with Nrecon V1.4 software
(SkyScan, Belgium), bone structure was analyzed using
CTan software (SkyScan, Belgium). The newly mineralized
bone volume fraction in the defect cavity was deﬁned as the
BV/TV parameter (Bone Volume/Tissue Volume ratio). For
C35 ceramics, global segmentation was determined in order
to separate newly mineralized elements from C35 ceramics
background using the CTan software histogram tool to
threshold gray level values.
2.3.2 Histological examinations
Following µCT scanning, undecalciﬁed paraformaldehyde-
ﬁxed femurs were successively dehydrated in graded etha-
nol solutions and xylene. Then, femurs were embedded in
Technovit® resin (Heraeus Kulzer GmbH, Wehrheim,
Germany) for 5 days at −20 °C. Serial 5 µm-thick long-
itudinal sections were obtained (Leica microtome, Den-
mark) and stained with Masson–Goldner’s trichrome to
identify bone structures, ﬁbrous tissue and bone marrow
cells. Alcian blue dye allowed hydrogel fragments identi-
ﬁcation. Staining for bone speciﬁc-alkaline phosphatase
(ALP) and tartrate-resistant acidic phosphatase (TRAP)
activities were performed to reveal mature osteoblasts and
osteoclasts, respectively [26, 27]. Stained sections were
imaged on a DMRB microscope (Leica) connected to a
Sony DXC930 color video camera. To analyze ALP and
TRAP activities and blood vessel density, 5 consecutive
sections were randomly chosen. From each section, neo-
vascularization and ALP positive osteoblasts or TRAP
positive osteoclasts were estimated in the randomly chosen
ﬁeld of 500 µm2 on a semiquantitative scale: (0) None; (1)
Low; (2) High by 2 blinded pathologists. For some samples
at day 30, number of vessels was manually counted in the
defect area.
Detection of Quantum Dot®-labeled MSCs and MAR
measurements on bone sections were achieved using a
ﬂuorescence microscope (Olympus IX71, Melville, NY)
connected to a spot Sony SE digital camera. For MAR
measurements (µm/day), the distance between the two
ﬂuorescent calcein lines (corresponding to the position of
the mineralization front by the time of the calcein injec-
tions) was measured using a semi-automatic image analyzer
software (Histolab, Microvision, France). As a control,
MAR was determined at a distance >3 mm from the defect
site.
2.3.3 Statistical analysis
For each experimental group, values are expressed as mean
± standard error of the mean (SEM). Statistical comparisons
were made by using one or two ways analysis of variance
(ANOVA) tests for MAR and BV/TV values, respectively.
Statistical differences were considered as signiﬁcant when P
values < 0.05. Considered parameters for BV/TV statistical
analysis are the experimental time and the bone defect
treatment. Whenever ANOVA yielded signiﬁcant interac-
tion difference, a Tukey’s HSD post-hoc test was thus
performed. A statistical software package R 3.0.1 (Vienna,
Austria) was used to achieve statistical comparisons in this
study.
3 Results
3.1 In vitro colonization of scaffolds by MSCs
After a gentle apposition and 4 days of rat MSCs culture,
C35 granules were massively colonized by cells as assessed
by trypan blue staining (Fig. 1a) and scanning electron
microscopy (Fig. 1b, c). MSCs were preferentially localized
on the C35 surface or near the pore entrances.
Clear and transparent hydrated hydrogels (Fig. 1e)
allowed for a direct observation of large MSCs clusters
spotted inside the hydrogel pores (50–200 µm diameters,
Fig. 1f), in the entire thickness of the scaffold thus vali-
dating the instantaneous cellularization of hydrogels with
MSCs.
3.2 3D micro-computed tomography analysis
Figure 2 shows representative µCT scan images of the bone
defect cavity illustrating bone healing progression on post-
surgery day 7, 30, and 90 in all experimental groups. The
control group generated negligible mineralized tissue within
the defect cavity, up to day 90. The absence of any cortical
bone restoration was also clearly evidenced. MSCs
administration enhanced bone formation and was char-
acterized by the development of bony spikes as early as
30 days after implantation. Furthermore, a partial closure of
the cortical defect was achieved with MSCs on day 90.
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A different bone repair pattern was noticed depending on
the nature of the implanted scaffold. Hydrogels combined or
not with MSCs induced a cortical bone-like mineralization
on the edges of the defect as early as day 7 and this bone
formation pathway was sustained up to day 90. In addition,
cancellous bone-like components were detected in the
cavity center. The C35 ceramics associated or not with
MSCs supported newly mineralized bone around granule
surfaces on day 30. On day 90, some internal pores of the
granules appeared to be partially ﬁlled with newly synthe-
sized bone but C35 ceramics failed to be resorbed.
The µCT scan allowed quantifying the newly synthesized
bone in the medullary cavity (Fig. 3). On day 7, BV/TV
values in the medullary cavities were similar in all experi-
mental groups (from 4 to 9%). On day 30, BV/TV for the
control group remained unchanged (6.0 ± 2.5%) when
compared to day 7 (4.7 ± 2.7%). Interestingly, the implan-
tation of both scaffolds signiﬁcantly increased medullary
cavity BV/TV values, reaching 16.6± 1.7% with C35
ceramics (p= 0.004) and 9.0± 2.6% with hydrogels (p=
0.049) on day 30. At this time, MSCs delivery induced a
signiﬁcant increase in BV/TV values (p= 0.017 with
Fig. 2 Representative 3D micro-
CT images of the rat femoral
distal end for each group on
days 7, 30, and 90. Untreated
defects showed very few
mineralization within the defect
even after 3 months. Hydrogels
induced a cortical bone-like
mineralization on the sides of
the defect as early as post-
surgery day 7. C35 were
partially covered with new bone
on post-surgery day 30
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ANOVA two parameters) by +20% in control group
(“control” vs. “MSC”), +16% in C35 group (“C35” vs. “C35
+MSC”) and +61% in hydrogel group (“Hydrogel” vs.
“Hydrogel+MSC”).
On day 90, the BV/TV value in the medullary cavity of
control rats was only 10.6± 1.9% highlighting the inefﬁ-
ciency of the natural bone healing process to restore the
original bone integrity. To the opposite, both tested scaf-
folds exhibited impressive osteoconductive properties since
the augmentation of BV/TV values was sustained, reaching
26.5± 0.5% for C35 ceramics (p< 0.001) and 20.6± 3.9%
for hydrogel (p< 0.001). The initial addition of MSCs
failed to signiﬁcantly modify the BV/TV values in the
medullary cavity of control and biomaterial-treated rat
femurs at this time.
3.3 Histological studies
Quantum dot®-labeling gave important clues on the dis-
tribution of delivered MSCs within the bone defect. Both in
untreated defect and hydrogel group, labeled MSCs were
observed in the bone defect on day 7 mainly located on the
edges of the defect (Fig. 4a, b), or close to the ceramic
surfaces (Fig. 4c, d). On day 30, engrafted MSCs were
sparser within the entire defect area. Some labeled cell
clusters appeared to be entrapped in the bone matrix of the
newly synthesized bone components (Fig. 4e, f). On day 90,
labeled MSCs were not detected anymore in the bone defect
area.
The presence of ALP positive osteoblasts was investi-
gated in all six groups. Some were detected on the cavity
sides as well as on newly synthesized bone trabeculae in the
defect area whatever the considered experimental times, but
only in the MSC-containing groups (semi-quantitative
scoring= 1). Furthermore, MAR values which reﬂect the
rate of new bone deposition, and thus indicate the speed of
repair, were similar, ranging between 3.8 and 5.2 µm/day,
independently of the considered experimental groups, in
medullary cavities and in unlesioned bony areas of all rats
(Fig. 5).
Masson–Goldner’s trichrome staining conﬁrm data
observed by µCT scan image analysis concerning newly
mineralized bone and provide additive information on the
nature of non-mineralized tissue in the medullary cavity
(Fig. 6). As an overall comment, histological analyses
excluded the presence of any cartilaginous tissue formation
or endochondral ossiﬁcation, thus suggesting an exclusive
intramembranous bone formation pattern in all animal
groups. From day 0 to day 90, a minimal bone healing with
a prominence of poorly vascularized ﬁbrous connective
tissue in the medullary cavity of control rats was observed.
MSC group supported bone repair as characterized by a
partial closing of the cortical defect and the presence of
newly synthesized trabeculae, however restricted to the
edges of the defect.
With ceramics, newly-mineralized deposits were spotted
on granule surfaces on day 30 and the thickness of miner-
alized tissue increased on day 90. In medullary cavity areas
not occupied by ceramic granules, typical bone marrow
cells were shown in association with rare little trabecular-
like spikes. Interestingly, newly formed bone in the C35
macropores was exclusively detected when MSCs were
combined to C35 granules. Mineral deposits around granule
surfaces were associated to double calcein layers while in
internal pores a unique calcein layer was observed sug-
gesting a delayed mineralization (Fig. 5e, f).
When using the hydrogel as a bone repair support, a
large amount of ﬁbrous tissue was found surrounding the
Fig. 3 Bone volume fraction
(BV/TV) for each group at 7, 30,
and 90 days after surgery in the
defect area. Given values are the
mean BV/TV ± SEM for each
experimental group. Signiﬁcant
differences (p< 0.05) when
comparing a: effect of time
within a considered group. b:
each group to its respective
control group for a deﬁned
experimental time. c: each group
with MSCs to its respective
group without MSCs for a
deﬁned experimental time
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gel in the medullary cavity on day 7. On day 30, large bone
ﬁlling with newly regenerated bone marrow cells was
achieved. At this time, an important bone mineralization
occurred at the medullary cavity periphery leading to the
formation of a thick shell-like compact bone structure
(Figs 6 and 8). Newly-synthesized trabecular bony spikes
were also detected within the cavity area.
According to the semiquantitative scale evaluation,
neovascularization was not detectable in control animals
and those administered with MSCs, hydrogel or ceramic
Fig. 5 Calcein labeling of mineralization fronts in the defect area for
each group with MSCs 30 days after surgery. Injections of ﬂuor-
ochrome were performed 12 and 3 days before sacriﬁce. a Control;
b MSC; c Hydrogel+MSC; d C35+MSC; Magniﬁcation of (D) on
the C35 surface e and in a pore f
Fig. 4 Fluorescent staining of MSCs in the defect area 7 days (Von
Kossa staining, bone in black) and 30 days (Masson-Goldner’s tri-
chrome staining, bone in blue) after surgery. Cells were labeled with
quantum dots prior to implantation. Merging of photomicrographs
obtained under normal light or under UV excitation with a speciﬁc
ﬁlter allows the detection of labeled cells close to the edges of the
defect both in control and hydrogel groups at day 7 (a, b), or close to
ceramic surfaces at day 7 (c, d), and both in new bone (e) and ﬁbrous
tissue (f) at day 30
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alone. When hydrogel was combined to MSCs, neovascu-
larization was detected at day 30, at scale 2 using semi-
quantitative method and 2.4± 1.6 vessels/mm2 in samples
submitted to manual counting; there was a trend to increase
at day 90 (3.7 ± 2.6 vessels/mm2), while at this time, vessel
number was estimated to scale 1 (0.5 ± 0.2 vessels/mm2)
after implantation of MSCs with ceramics.
Histological analysis conﬁrmed that no resorption of C35
granules was achieved even on day 90 despite a noticeable
physiological response, as suggested by the massive pre-
sence of TRAP+-osteoclasts at the granule surface (Fig. 7).
This is in contrast with the fast hydrogel degradation that
was almost completely resorbed on day 30, estimated to




stained undecalciﬁed rat femoral
defects implanted with
hydrogels or C35 ceramics with
or without MSCs on days 7, 30,
and 90. Mineralized tissue is
blue, ﬁbrous tissue is red/pink,
ceramics have a white shadowy
appearance. Note that depending
on the cutting angle, one cannot
see the defect opening
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4 Discussion
Increasing evidences from the literature indicate that tissue-
engineering is a promising alternative to autologous bone
graft for repair of critical size bone defects, but optimal
scaffold remains to be deﬁned. An ideal matrix for regen-
erating large bone defects should promote osteogenic dif-
ferentiation of host MSCs, thanks to its own intrinsic
chemical and structural properties, and promote the growth
of a dense mineralized bone tissue after its implantation in
the defect. Although several stem cells based products
delivered through biomaterials have been tested in different
models of in vivo bone repair, comparisons in a same model
are rarely achieved. Here, in a rat model of large bone defect
in which mechanical constraint applied to the newly formed
bone is preserved, we evidenced the osteogenic properties
of resorbable, soft, polysaccharide hydrogel in comparison
with standard calcium-phosphate ceramic. Both hydrogel
and ceramic improved bone repair by 20 and 26% of newly
mineralized bone respectively, as compared to control at
3 months. The concomitant presence of ALP and TRAP-
positive cells in the repair area indicates an active bone
remodeling process. However, repair mechanism and
resorption kinetics were strikingly different.
Using C35 ceramic, newly synthesized bone was mainly
located on the granule periphery surface conﬁrming the
biocompatibility and osteoconductivity of these ceramics.
Only tiny bone formation was detected in the internal pores
of the C35 granules as assessed by µCT measurements,
calcein labeling and histological observations. Indeed, both
in vitro and in vivo bone integration into HA/TPC ceramics
depend on the porosity and the pore interconnectivity of the
scaffold [5, 28, 29]. According to the physical character-
istics given by the manufacturer, the pore sizes of our C35
ceramics range between 100 and 400 µm and the macro-
porosity is about 60% (pores larger than 300 µm). These
parameters should have ensured in vivo osteogenesis. Poor
interconnectivity could be involved in the limited bone
Fig. 7 TRAP-hematoxylin
staining (Red color: osteoclasts).
Ceramic surfaces in the “C35+
MSC” group on post-surgery
days 30 and 90; and newly
mineralized bone in the
“Hydrogel+MSC” group on
days 30 and 90
Fig. 8 In vivo hydrogel fate overtime. Light microscopy photographs of undecalciﬁed rat femoral defects 7, 30, or 90 days after surgery (Alcian
blue staining)
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formation, remodeling in internal pore and subsequent
observed biodegradability of HA/TCP ceramics [30]. Our
histological and µCT data indicated an absence of resorp-
tion even at 3 months or in long term follow-up animals
(6–7 months, data not shown) after biomaterial implanta-
tion, despite the presence of numerous TRAP positive-
mature cells all around the ceramic granules (Fig. 7). This
conﬁrms several clinical investigations, in which patients
treated for large varus deformity and osteoarthritis with
proximal tibial opening-wedge osteotomy using porous β-
TCP wedges (Ceraver) demonstrated no complete ceramic
wedge resorption after a mean follow-up of 10 years [31,
32] although β-TCP ceramics have higher resorption rates
than ceramics made of HA [33].
In contrast, the pullulan/dextran-based hydrogel tested
herein presented impressive resorption capacity, consistent
with our previous works. In a rat animal model, a porous
FITC-scaffold implanted on infarcted cardiac tissue was
degraded in less than a month, and only remnants of the
hydrogel were seen embedded or integrated into the
adjacent tissue on heart sections [34]. Physiological
enzymes such as acid and alcaline phosphatases might have
contributed to this in vivo degradation. Indeed, STMP
cross-linking mechanism creates phosphoester linkages that
are sensitive to phosphatase hydrolysis [35]. Similarly, we
observed a fast degradation of porous polysaccharide
hydrogel when implanted subcutaneously in adult mice
[36]. This rapid hydrogel resorption was not a drawback for
an efﬁcient bone repair and supports a different repair
mechanism with bone regeneration occurring on the edges
of the bone defect cavity and slowly joining by the time the
center of the defect up to ensure a complete bone repair in
some animals. After 90 days, the newly-mineralized bone
level in the medullar cavity of rats treated with hydrogel
reached
the same amount of newly-formed bone in the defect of
animals implanted with C35 ceramics (BV/TV values ran-
ging from 20 to 25% for either “Hydrogel” or “C35” groups
on day 90). A growing interest for polymer hydrogels
to enhance bone healing is arising. Soft synthetic [37] or
natural polymers [38] offer several advantages including
easy shaping capacity, radio-transparency and high resorp-
tion ability. The 3D structure and permeability of these
polymers have a deep impact on cell physiology,
modulating viability, proliferation or differentiation of var-
ious progenitor cells, as well as facilitating oxygen and
nutrient delivery, or protecting soluble factors and osteo-
progenitor cells [1, 24, 38–40]. We think that MSCs colo-
nize the porous hydrogel and form aggregates of living cells
in large diameter pores, that may favor interactions between
cells, thereby promoting osteogenic differentiation and
subsequent production of mineralized matrix [41]. Various
mammalian defect models treated with polysaccharide-
derived hydrogels exhibited enhanced tissue or bone repair,
as reviewed in [1, 38, 42]. Recently, a novel polymer
hydrogel of sugarcane molasses appeared to be a good
candidate to treat calvarial bone defects in rats, in associa-
tion with Bone Morphogenetic Proteins (BMPs) [43]. In
patients, hyaluronan-based hydrogels associated with BMP-
2 greatly enhanced the healing of critical-size cranial defects
[44] or alveolar cleft defects [45], and alginate-agarose
hydrogels combined with autologous chondrocytes sig-
niﬁcantly improved clinical outcome in patients suffering
from chondral or osteochondral defects over a 2-year fol-
low-up [46].
The physical and chemical properties as well as the
interactions of this hydrogel with several cell lines were
extensively studied [17, 18, 24, 34, 47, 48]. The hydrogel
used here have also been more recently evaluated as an
original base of a composite material in association with
nanocrystalline hydroxyapatite particles (nHA); implanted
in orthotopic preclinical models of critical size defects, in
small and large animals, in three different bony sites, in
goat, the hydrogel+ nHA induced a highly mineralized
tissue whatever the site of implantation, as well as osteoid
tissue and bone tissue regeneration in direct contact to the
matrix [49].
In the present study, we also assessed the inﬂuence of
MSCs delivery associated with either C35 ceramics or
hydrogels since MSCs are a major contributor to the natural
bone repair process. Using Quantum dot®-labeling, we
evidenced that the number of delivered MSCs engrafted in
the bone defect cavity was important on day 7 but these cell
numbers decreased dramatically by 30 days after implan-
tation, independently of the considered experimental
groups. Some of these MSCs appeared to be entrapped in
the newly-mineralized bone and seem to locate more at the
periphery of the scaffold, suggesting that (a) engrafted
MSCs migrated and differentiated into mature osteoblasts to
ensure bone formation and (b) a direct involvement of
implanted MSCs in the bone healing process. These
observations correlates with the Lalande study [48] that
showed a migration of labeled adipose derived stromal cells
from the center to the periphery of the hydrogel, associated
with a better bone tissue regeneration process. Ninety days
after implantation, labeled MSCs could not be detected
anymore and the absence of MSC-enhanced bone repair at
this time was consistent with the disappearance of the
delivered MSCs. This observation could argue in favor of a
sequential multiple MSC administration strategy all over the
repair process kinetic, to support a complete bone regen-
eration. At day 30, MSCs delivery induced a signiﬁcant
increase in bone formation particularly in the hydrogel
group (+61%) and furthermore, a greater osteodifferentia-
tion capacity of cultured MSCs could be expected by
expanding these progenitors in the presence of platelet
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lysate [20, 50, 51] rather than FGF as we performed here.
We also evidenced that addition of MSCs greatly improved
angiogenesis in the bone defect cavity of rats treated mainly
with hydrogels, since MSCs promoted blood vessel growth
within the newly-formed thick shell-like bone structure at
the medullar cavity periphery. This indicated the positive
inﬂuence of the rapid hydrogel resorption on bone repair.
Furthermore, hydrogels could provide a protective envir-
onment for in vivo MSC survival as they could retain
growth factors produced by MSCs and favor cell interac-
tions by inducing aggregates composed of MSCs and pro-
genitor endothelial cells. Co-cultures of hMSCs and
progenitor-derived endothelial cells in the porous hydrogel
induced the formation of cellular aggregates that promoted
in vitro and ectopic osteogenesis in mice [47].
This is an important physiological aspect since bone is a
highly metabolic tissue requiring an abundant vascular
supply throughout its structure for growth, remodeling, and
repair abilities [52]. Our results about the improvement of
bone repair and angiogenesis obtained with the implantation
of MSCs are consistent with numerous previously published
studies [53].
Altogether, our results suggest that bone healing
improvement provided by MSC delivery could rely on both
a paracrine activity triggered by cytokines secreted from
MSCs and a direct MSC involvement in bone repair process
through their differentiation into mature osteoblasts
responsible for bone formation. MSCs are promising can-
didates for successful clinical applications and several
clinical trials have already been attempted as summarized
by Park and colleagues [54].
5 Conclusions/Perspectives
The pullulan/dextran-based hydrogel tested herein evi-
denced signiﬁcant osteogenic properties combined with
rapid resorption ability making it a promising alternative or
complementary biomaterial to HA/TCP ceramics for
bone repair support. Indeed, the different repair mechanisms
triggered by both scaffold support the possible combi-
nation of their properties. In addition, the hydrogel cap-
ability to deliver growth factors or to entrap progenitor
cells such as MSCs or endothelial progenitor cells
could also be advantageously exploited and possibly
enhanced by modifying hydrogel structure and stiffness.
With their easy shaping capacity, hydrogel should be of
particular interest for maxillo-facial and short-bone
regeneration.
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